1. Management of Coats’ disease with RazumabTM (World’s first biosimilar ranibizumab) and laser photocoagulation: A case report
- Author
-
Bhagwati Prasad Sharma and Shashikant Sharma
- Subjects
Best corrected visual acuity ,medicine.medical_specialty ,genetic structures ,business.industry ,010102 general mathematics ,Biosimilar ,medicine.disease ,01 natural sciences ,eye diseases ,Neuro-ophthalmology ,03 medical and health sciences ,Near vision ,0302 clinical medicine ,Ophthalmology ,030221 ophthalmology & optometry ,medicine ,Pediatric ophthalmology ,sense organs ,Coats' disease ,0101 mathematics ,Ranibizumab ,Medical science ,business ,medicine.drug - Abstract
We report a case of a 19-year-old Indian male with stage 2 Coats’ disease who was managed with monthly intravitreal biosimilar ranibizumab injections (n=3) along with laser photocoagulation in the right eye. Post-treatment, significant reductions were seen in the exudation, angioma-like lesions, central macular thickness and edema in the retina. At the last follow-up at 9 months after intravitreal biosimilar ranibizumab initiation, distant vision improved from best corrected visual acuity (BCVA) of 5/60 at baseline to 6/18, and near vision from ‘not able to read’ to N/12 in the right eye. Keywords: Biosimilar, Coats’ disease, Laser photocoagulation, Ranibizumab.
- Published
- 2021